RELMADA THERAPEUTICS INC
Relmada Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel medications for the treatment of chronic pain.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding RELMADA THERAPEUTICS' stock with a target price of $0.87, indicating limited growth.
Financial Health
Relmada Therapeutics is showing solid cash flow and book value, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RLMD
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial Milestones Matter
Clinical readouts and regulatory steps tend to drive price moves; positive data can boost prospects but results can also disappoint.
Binary Outcomes Risk
Development-stage outcomes are often binary — success or failure — creating high volatility. Consider diversification to manage risk.
Funding And Partnerships
Cash runway and strategic partnerships can alter the company’s path; watch financing announcements that may dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
